EXHIBIT 99.1

PRESS RELEASE


XTRANA ANNOUNCES SETTLEMENT OF LITIGATION WITH TRINITY BIOTECH

Monday June 23, 2003

BROOMFIELD,  Colo.-- June 23,  2003--Xtrana,  Inc. (OTCBB: XTRN) announced today
that it has entered into a settlement agreement with Trinity Biotech,  plc, with
regard to a lawsuit  filed by Trinity on December 19,  2002,  and a counter suit
filed against Trinity by Xtrana on January 17, 2003.

Trinity's lawsuit alleged breach of contract,  breach of the implied covenant of
good  faith  and  fair  dealing,  fraud,  negligent  misrepresentation,   unjust
enrichment, and violation of the Delaware Consumer Fraud Act in conjunction with
Xtrana's  sale of its  Hemostasis  business to Trinity.  Xtrana's  counter  suit
alleged tortuous  interference with prospective  economic  advantage,  breach of
contract, breach of the covenant of good faith and fair dealing, and declaratory
judgment as a result of Trinity's  attempt to avoid its contractual  obligations
to Xtrana by instituting  litigation to force Xtrana to renegotiate the terms of
the sale of its Hemostasis business.

As a result of the settlement:  (a) both parties have dismissed all claims under
the existing  litigation with prejudice;  (b) both parties are released from any
further claims or causes of action in connection with the sale of the Hemostasis
assets to Trinity on December 21, 2001; and (c) Trinity has paid $1.5 million to
Xtrana,  representing  a prepayment of the remaining  outstanding  secured notes
resulting from the sale of the Hemostasis  assets originally due on December 21,
2003, and December 21, 2004, less a financial discount for the prepayment.

"We have  always  felt that  Trinity's  suit had no  merit,  and  settling  this
litigation  has eliminated the  significant  financial  burden of defending that
suit for Xtrana," said Tim Dahltorp,  Xtrana's CEO.  "Although we were confident
in our counter  suit  against  Trinity,  the risks  inherently  associated  with
litigation  were not worth chasing the prospects of recovering  attorney's  fees
and damages.  The prepayment of the notes  combined with the  elimination of our
continuing legal costs relating to the litigation will substantially improve the
Company's  short-term  liquidity  position.  The  combination  of  our  improved
liquidity, combined with the elimination of the negative connotations associated
with the litigation will be positive  factors in pursuing our ongoing process of
attracting a strategic alliance with an appropriate partner, a process currently
being managed by our investment banker, West Ridge Associates."

Xtrana,  Inc.  develops,  manufactures and markets novel nucleic acid extraction
kits and detection  systems for use in molecular  diagnostics,  drug  discovery,
forensics,  research,  clinical and life sciences  markets.  To learn more about
Xtrana, visit the Company's web site at www.xtrana.com.

This Press Release contains forward-looking  statements (identified by the words
"estimate,"  "anticipate," "expect," "believe," and similar expressions),  which
are based upon management's


                                       5





current  expectations and speak only as of the date made. These  forward-looking
statements  are subject to risks,  uncertainties  and  factors  that could cause
actual  results  to  differ  materially  from  the  results  anticipated  in the
forward-looking  statements  and include,  but are not limited to,  competitors'
pricing  strategies and  technological  innovations,  changes in health care and
government regulations, litigation claims, foreign currency fluctuation, product
acceptance,  as well as other factors  discussed in the Company's last Report on
Form 10-KSB.

--------------------------------------------------------------------------------
Contact:
     Xtrana, Inc.
     Timothy Dahltorp, 303/466-4424


                                       6